Okinawa Buys Three Genome Analyzers To Boost Biopharma Research
This article was originally published in PharmAsia News
Executive Summary
With financial support from the prefectural government, the Okinawa Health Biotechnology Research and Development Center has invested ¥0.29 billion and purchased three genome analyzers in an effort to speed up genetic analysis and boost research efficiency. A single facility with three such high-speed systems is a rarity and is the largest of its size in Japan. The move is aimed to improve biopharma research in Okinawa and provide a preferred research destination for pharmaceutical companies. Okinawa is known for its unique subtropical location and the population with the highest longevity in Japan. The Prefecture has actively promoted biopharma research activities to become a nationwide leader. According to local economic authorities, two leading Asian biopharma research areas, in Singapore and Beijing, have been actively investing in genome analyzers to accelerate research activities; Okinawa hopes to be competitive in Asia as well.(Click here for more-Japanese language